Back to top

Image: Bigstock

Is Amedisys (AMED) a Great Growth Stock?

Read MoreHide Full Article

Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, they can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.

One such company that might be well-positioned for future earnings growth is Amedisys, Inc. (AMED - Free Report) . This firm, which is in the Medical – Outpatient and Home Healthcare industry, saw EPS growth of 64.3% last year, and is looking great for this year too.

In fact, the current growth estimate for this year calls for earnings-per-share growth of 21%. Furthermore, the long-term growth rate is currently an impressive 16.4%, suggesting pretty good prospects for the long haul.

Amedisys, Inc. Price and Consensus

And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 5.5%. Thanks to this rise in earnings estimates, AMED has a Zacks Rank #1 (Strong Buy) which further underscores the potential for outperformance in this company. You can see the complete list of today’s Zacks #1 Rank stocks here.

So if you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider AMED. Not only does it have double-digit earnings growth prospects, but its impressive Zacks Rank suggests that analysts believe better days are ahead for AMED as well.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Amedisys, Inc. (AMED) - free report >>